Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826464 | 0.93 | ALDH1A1 (0.85) | ALDH1A1LMNAKMT2APKMNFE2L2 | |
| SCHEMBL826463 | 0.93 | ALDH1A1 (0.85) | ALDH1A1LMNAKMT2APKMNFE2L2 | |
| SCHEMBL827806 | 0.86 | ALDH1A1 (0.74) | ALDH1A1LMNAKMT2APKMNFE2L2 | |
| SCHEMBL827807 | 0.86 | ALDH1A1 (0.74) | ALDH1A1LMNAKMT2APKMNFE2L2 | |
| SCHEMBL826538 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAKMT2APKMNFE2L2 | |
| SCHEMBL826539 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAKMT2APKMNFE2L2 | |
| SCHEMBL1122729 | 0.83 | ALDH1A1 (0.71) | ALDH1A1LMNAPTGES2HDAC4HDAC1 | |
| SCHEMBL7259173 | 0.83 | ALDH1A1 (0.62) | ALDH1A1LMNAKMT2APKMNFE2L2 | |
| SCHEMBL1122889 | 0.81 | ALDH1A1 (0.59) | ALDH1A1LMNAKMT2APKMNFE2L2 | |
| SCHEMBL827377 | 0.81 | KMT2A (0.72) | ALDH1A1LMNAKMT2APKMPTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379508-B9 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-02-09 | — | — | EP | claimed |
| EP-1379508-B1 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1379508-A4 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2005-12-28 | — | — | EP | claimed |
| EP-1379508-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2004-01-14 | — | — | EP | claimed |
| US-6646009-B2 | Use against proliferative disorders including cancer, and as a radioprotective compound for normal cells from ionizing radiation | Temple University — Of Commonwealth System of Higher Education | 2003-11-11 | — | — | US | claimed |
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | ONCONOVA THERAPEUTICS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002067865-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-06 | — | — | WO | claimed |
| EP-1379508-B9 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-1379508-B1 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1379508-A4 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1379508-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6646009-B2 | Use against proliferative disorders including cancer, and as a radioprotective compound for normal cells from ionizing radiation | Temple University — Of Commonwealth System of Higher Education | 2003-11-11 | — | — | US | disclosed |
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | ONCONOVA THERAPEUTICS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002067865-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | HCCS, NAT1, ARSA | ALDH1A1 678/4885LMNA 3112/4885KMT2A 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.